Analysts See $0.56 EPS for Heska (HSKA); United Therapeutics (UTHR) Has 0.99 Sentiment

February 21, 2018 - By Marie Mckinney

Analysts expect Heska Corporation (NASDAQ:HSKA) to report $0.56 EPS on February, 28 before the open.They anticipate $0.10 EPS change or 21.74% from last quarter’s $0.46 EPS. HSKA’s profit would be $4.06M giving it 26.66 P/E if the $0.56 EPS is correct. After having $0.40 EPS previously, Heska Corporation’s analysts see 40.00% EPS growth. The stock decreased 2.19% or $1.34 during the last trading session, reaching $59.71. About 66,631 shares traded. Heska Corporation (NASDAQ:HSKA) has risen 162.64% since February 21, 2017 and is uptrending. It has outperformed by 145.94% the S&P500.

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company has market cap of $5.83 billion. The companyÂ’s product candidates include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, a once-daily PDE-5 inhibitor to enhance the exercise ability in PAH patients. It has a 11.98 P/E ratio. It also provides Unituxin for the treatment of pediatric patients with high-risk neuroblastoma who achieve a partial response to prior first-line multiagent multimodality therapy.

Krensavage Asset Management Llc holds 12.66% of its portfolio in United Therapeutics Corporation for 346,511 shares. Palo Alto Investors Llc owns 1.76 million shares or 8.7% of their US portfolio. Moreover, Argentiere Capital Ag has 5.24% invested in the company for 116,152 shares. The New York-based Armistice Capital Llc has invested 2.07% in the stock. Dock Street Asset Management Inc, a Connecticut-based fund reported 36,151 shares.

Since January 1, 0001, it had 0 insider purchases, and 11 sales for $1.54 million activity.

The stock increased 0.02% or $0.03 during the last trading session, reaching $134.96. About 546,315 shares traded or 34.40% up from the average. United Therapeutics Corporation (UTHR) has risen 9.78% since February 21, 2017 and is uptrending. It has underperformed by 6.92% the S&P500.

Heska Corporation develops, manufactures, and markets advanced veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company has market cap of $432.53 million. It operates through two divisions, Core Companion Animal Health; and Other Vaccines, Pharmaceuticals and Products. It has a 31.31 P/E ratio. The Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure white and red blood cell count, platelet count, and hemoglobin levels in animals; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and IV pumps.

Among 8 analysts covering Heska Corp (NASDAQ:HSKA), 4 have Buy rating, 0 Sell and 4 Hold. Therefore 50% are positive. Heska Corp had 13 analyst reports since August 25, 2015 according to SRatingsIntel. The stock of Heska Corporation (NASDAQ:HSKA) has “Buy” rating given on Wednesday, March 1 by Benchmark. On Friday, April 1 the stock rating was initiated by CL King with “Neutral”. The stock of Heska Corporation (NASDAQ:HSKA) has “Neutral” rating given on Thursday, January 26 by CL King. The firm earned “Hold” rating on Thursday, August 4 by Gabelli. The rating was upgraded by TheStreet to “Hold” on Tuesday, August 25. Gabelli maintained Heska Corporation (NASDAQ:HSKA) on Tuesday, August 1 with “Hold” rating. Benchmark initiated Heska Corporation (NASDAQ:HSKA) on Tuesday, November 29 with “Buy” rating.

Investors sentiment increased to 1.26 in 2017 Q3. Its up 0.01, from 1.25 in 2017Q2. It improved, as 16 investors sold Heska Corporation shares while 37 reduced holdings. 24 funds opened positions while 43 raised stakes. 5.53 million shares or 0.49% more from 5.51 million shares in 2017Q2 were reported. Sg Americas Ltd Co accumulated 1,226 shares or 0% of the stock. Gamco Investors Incorporated Et Al reported 35,000 shares or 0.02% of all its holdings. Fifth Third Savings Bank owns 376 shares. State Of Alaska Department Of Revenue reported 1,273 shares. 31,078 are held by Ranger Investment Mngmt Lp. Clarivest Asset Mngmt Limited Liability Corporation reported 23,549 shares stake. Kbc Group Nv reported 20,162 shares stake. Geode Capital Lc reported 0% of its portfolio in Heska Corporation (NASDAQ:HSKA). The United Kingdom-based Gsa Capital Ptnrs Limited Liability Partnership has invested 0.08% in Heska Corporation (NASDAQ:HSKA). Louisiana State Employees Retirement holds 0.01% or 2,600 shares. Wedge Management L L P Nc reported 0.01% stake. Bancorporation Of Nova Scotia has invested 0.01% in Heska Corporation (NASDAQ:HSKA). Royal National Bank Of Canada holds 0% or 1,388 shares. Raymond James Na reported 8,953 shares. Bancorp Of Ny Mellon Corporation has invested 0% in Heska Corporation (NASDAQ:HSKA).

Since August 30, 2017, it had 0 insider purchases, and 2 insider sales for $348,184 activity. Shares for $84,327 were sold by Wisnewski Nancy on Thursday, August 31. $263,857 worth of Heska Corporation (NASDAQ:HSKA) was sold by McMahon John on Wednesday, August 30.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts

>